Physician profile
Carl Taylor Geraldson
NPI 1659767671
$8,250.12
in general payments reported to CMS, 2019-2025
23 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $887 · 2023: $1,903 · 2024: $3,264 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069 · Travel and Lodging: $3,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,068.59 |
| Travel and Lodging | $3,295.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $2,596.27 | 2024-2025 | Cryovalve Sg Pulmonary Human Heart Valve, Cardiac Non-Synergraft, On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder |
| Atricure, INC. | $1,416.64 | 2022-2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Bolton Medical INC | $1,374.47 | 2025 | Treo Abdominal Stent-Graft System |
| Medtronic, INC. | $528.02 | 2025 | Valiant Captivia, Endurant Iis, Penditure |
| Baxter Healthcare | $442.14 | 2022-2024 | Tisseel, Preveleak, Coseal |
| Abiomed | $404.43 | 2023-2025 | Impella |
| Edwards Lifesciences Corporation | $327.25 | 2022-2024 | Hemosphere, Swan-Ganz |
| Getinge USA Sales, LLC | $192.17 | 2022-2023 | Cardiohelp |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.19 | 2023-2024 | Lifevest |
| Stryker Corporation | $168.56 | 2023 | Spy-Phi System |
| Cook Medical LLC | $125.38 | 2024 | Zenith Alpha |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $108.83 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.70 | 2023-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $86.61 | 2023-2024 | Onpattro |
| Novartis Pharmaceuticals Corporation | $54.92 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.59 | 2022-2023 | Repatha |
| Solventum Corporation | $23.75 | 2025 | V.A.C. Veraflo, Prevena |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $16.42 | 2023 | |
| Merck Sharp & Dohme LLC | $16.35 | 2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $14.27 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $13.81 | 2023 | Camzyos |
| Zoll Medical Corporation | $10.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Geraldson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.